The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

In two recent studies, this new shot reportedly nearly eliminated new infections in people at substantial risk of HIV.

The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthrou ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated ...

Gilead has won FDA approval for an HIV prevention shot that is administered only once every six months. When will low-income ...

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences’ twice-yearly injection to prevent HIV - a move the ...